Adjuvia Therapeutics

Adjuvia combines a proprietary astaxanthin conformation with a BBB-penetrant nanoparticle that spans cell and mitochondrial membranes rather than acting only in the cytosol. Issued and pending intellectual property covers extraction process, molecular conformation, and formulation.

Shared nanoparticle infrastructure is intended to reduce development cost across mitochondrial indications while oral administration supports long-term patient compliance without infusions or injections.

Adjuvia initially prioritizes rare mitochondrial diseases such as Friedreich's ataxia, where unmet need is high and clinical development can be concentrated. Broader mitochondrial dysfunction markets in aging, cardiometabolic disease, and fertility are described as expansion opportunities if early clinical data support the platform.

With an 8 million dollar Series Seed closed in July 2026, the near-term outlook centers on IND filing and first-in-human Phase 1 work, followed by a Phase 1/2 study in Friedreich's ataxia patients planned for early 2027.

ATI-105 is Adjuvia Therapeutics lead oral blood-brain barrier-penetrant lipid nanoparticle formulation of a novel astaxanthin molecular conformation. The asset is designed for multi-organ mitochondrial targeting with preclinical evidence of reduced reactive oxygen species and inflammation.

Development plans include IND submission, a Phase 1 healthy-volunteer study in Fall 2026, and a Phase 1/2 trial in Friedreich's ataxia patients in early 2027, while the same delivery architecture supports additional payload programs.